

The Medical Letter®

on Drugs and Therapeutics

GLP-1 and GIP/GLP-1 RECEPTOR AGONISTS FOR CHRONIC WEIGHT MANAGEMENT

Updated March 25, 2026

The Medical Letter®

Because the source matters.

To support more content like this, please consider making a [donation](#) or becoming a [subscriber](#).

The Medical Letter is a nonprofit organization* that relies solely on subscription fees and donations to support our mission of providing objective, practical, and timely information on drugs and therapeutics.

Our work relies on support from people like you who value credible, unbiased drug information that is free of any commercial interest.

For more information visit our [website](#) or call Customer Service at: 800-211-2769

*The Medical Letter is a nonprofit, tax-exempt organization under Section 501(C)(3) of the Internal Revenue Code.
Donations are tax-deductible as allowed by law.

GLP-1 and GIP/GLP-1 RECEPTOR AGONISTS FOR CHRONIC WEIGHT MANAGEMENT

Drug	Eligible Patients	Usual Dosage	Other Information
GLP-1 Receptor Agonists			
Liraglutide – Saxenda, and generic (Novo Nordisk) 18 mg/3 mL pens	- Adults with obesity, or overweight with ≥ 1 weight-related comorbidity - Children 12-17 years old who weigh >60 kg with obesity	Target: 3 mg SC once/day Titration: 0.6 mg once/day x 7 days; increase in 0.6-mg increments each week to 3 mg once/day	Mean placebo-corrected weight loss 4-5% at week 56 (in patients without type 2 diabetes)
Semaglutide – Wegovy (Novo Nordisk) 0.25, 0.5, 1 mg/0.5 mL; 1.7, 2.4 mg/0.75 mL pens	- Adults with obesity, or overweight with ≥ 1 weight-related comorbidity - Children 12-17 years old with obesity	Target: 1.7 or 2.4 mg SC once/week Titration: 0.25 mg SC once/week x 4 weeks, then 0.5 mg once/week for 4 weeks, 1 mg once/week x 4 weeks, 1.7 mg once/week x 4 weeks, and 2.4 mg once/week thereafter. If 2.4 mg is not tolerated, decrease to 1.7 mg	- SC: Mean placebo-corrected weight loss 10-15% at week 68 (in patients without type 2 diabetes; intent-to-treat population) - SC Wegovy is also FDA-approved to reduce the risk of MACE in adults with established CVD and obesity/overweight and for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
Wegovy HD 7.2 mg/0.75 mL pens	Adults with obesity, or overweight with ≥ 1 weight-related comorbidity, who are tolerating the 2.4-mg dose for at least 4 weeks and require additional weight reduction	If additional weight loss is needed in patients who tolerated 4 weeks of 2.4 mg once weekly, can increase to 7.2 mg SC once/week	SC: Mean weight loss 18.7% at 72 weeks (in intention-to-treat population)
1.5, 4, 9, 25 mg tabs	Adults with obesity, or overweight with ≥ 1 weight-related comorbidity	Target: 25 mg PO once/day Titration: 1.5 mg PO once/day x 30 days, then 4 mg once/day x 30 days, 9 mg once/day x 30 days, and 25 mg once/day thereafter	- PO: Mean placebo-corrected weight loss 11% at week 64 (in patients without type 2 diabetes; intent-to-treat population) - Oral Wegovy is also FDA-approved to reduce the risk of MACE in adults with established CVD and obesity/overweight
GIP/GLP-1 Receptor Agonist			
Tirzepatide – Zepbound (Lilly) 2.5, 5, 7.5, 10, 12.5, 15 mg/0.5 mL pens and vials	Adults with obesity, or overweight with ≥ 1 weight-related comorbidity	Target: 5, 10, or 15 mg SC once/week Titration: 2.5 mg SC once/week x 4 weeks, then 5 mg once/week x 4 weeks, then increase the dose in 2.5-mg increments every 4 weeks as needed (max 15 mg once/week)	- Mean placebo-corrected weight loss 12-15% at week 72 (in patients without type 2 diabetes; intent-to-treat population) - Also FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity

Obese = BMI ≥ 30 kg/m²; overweight = BMI ≥ 27 kg/m²; weight-related comorbidity = CV disease, hypertension, obstructive sleep apnea, type 2 diabetes, dyslipidemia